Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group

Clinical Trial

. 2008 May 1;26(13):2178-85.

doi: 10.1200/JCO.2007.14.8288.

Jeffrey A Sosman, Rene Gonzalez, F Stephen Hodi, Gerald P Linette, Jon Richards, James W Jakub, Muralidhar Beeram, Stefano Tarantolo, Sanjiv Agarwala, Gary Frenette, Igor Puzanov, Lee Cranmer, Karl Lewis, John Kirkwood, J Michael White, Chenghua Xia, Kiran Patel, Evan Hersh

Affiliations

PMID: 18445842
DOI: 10.1200/JCO.2007.14.8288

Clinical Trial

David F McDermott et al. J Clin Oncol. 2008.

Abstract

Purpose: This phase II study evaluated the efficacy and safety of sorafenib plus dacarbazine in patients with advanced melanoma.

Patients and methods: This randomized, double-blind, placebo-controlled, multicenter study enrolled chemotherapy-naive patients with stage III (unresectable) or IV melanoma. A total of 101 patients received placebo plus dacarbazine (n = 50) or sorafenib plus dacarbazine (n = 51). On day 1 of a 21-day cycle, patients received intravenous dacarbazine 1,000 mg/m(2) for a maximum of 16 cycles. Oral sorafenib 400 mg or placebo was administered twice a day continuously. The primary end point was progression-free survival (PFS) by independent assessment. Secondary and tertiary end points included time to progression (TTP), response rate, and overall survival (OS).

Results: Median PFS in the sorafenib plus dacarbazine arm was 21.1 weeks versus 11.7 weeks in the placebo plus dacarbazine arm (hazard ratio [HR], 0.665; P = .068). There were statistically significant improvements in PFS rates at 6 and 9 months, and in TTP (median, 21.1 v 11.7 weeks; HR, 0.619) in favor of the sorafenib plus dacarbazine arm. No difference in OS was observed (median, 51.3 v 45.6 weeks in the placebo plus dacarbazine and sorafenib plus dacarbazine arms, respectively; HR, 1.022). The regimen was well tolerated and had a manageable toxicity profile.

Conclusion: Sorafenib plus dacarbazine was well tolerated in patients with advanced melanoma and yielded an encouraging improvement in PFS. Based on these findings, additional studies with the combination are warranted in this patient population.

PubMed Disclaimer

Cited by

Current Advancements and Novel Strategies in the Treatment of Metastatic Melanoma.
Sood S, Jayachandiran R, Pandey S. Sood S, et al. Integr Cancer Ther. 2021 Jan-Dec;20:1534735421990078. doi: 10.1177/1534735421990078. Integr Cancer Ther. 2021. PMID: 33719631 Free PMC article. Review.
Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology.
Hess LM, Brnabic A, Mason O, Lee P, Barker S. Hess LM, et al. J Cancer. 2019 Jun 9;10(16):3717-3727. doi: 10.7150/jca.32205. eCollection 2019. J Cancer. 2019. PMID: 31333789 Free PMC article. Review.
Comparative efficacy and safety of combination therapies for advanced melanoma: a network meta-analysis.
An Q, Liu Z. An Q, et al. BMC Cancer. 2019 Jan 9;19(1):43. doi: 10.1186/s12885-018-5259-8. BMC Cancer. 2019. PMID: 30626368 Free PMC article.
Systemic Drug-induced Chronic Paronychia and Periungual Pyogenic Granuloma.
Wollina U. Wollina U. Indian Dermatol Online J. 2018 Sep-Oct;9(5):293-298. doi: 10.4103/idoj.IDOJ_133_18. Indian Dermatol Online J. 2018. PMID: 30258794 Free PMC article. Review.

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group - PubMed (original) (raw)